These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21039620)

  • 1. The impact of patient advocacy: the case of innovative breast cancer drug reimbursement.
    Nahuis R; Boon WP
    Sociol Health Illn; 2011 Jan; 33(1):1-15. PubMed ID: 21039620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two views on HDCT-ABMT breast cancer treatment controversy. Too experimental for insurers--or just too expensive?
    Carter RD; Coleman DM; Bennett JE
    Healthspan; 1992 Jan; 9(1):10-5. PubMed ID: 10117134
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing on the political front.
    Meyer C
    Am J Nurs; 1992 Oct; 92(10):56-60, 63-4. PubMed ID: 1466389
    [No Abstract]   [Full Text] [Related]  

  • 5. Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty first century.
    Zimmerman GM; Savage LM; Chandler DC; Maccarone Buonfigli M
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii93-100. PubMed ID: 15708949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The health policy pathfinder: an innovative strategy to explore interest group politics.
    Nannini A
    J Nurs Educ; 2009 Oct; 48(10):588-91. PubMed ID: 19731891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capitalising upon political opportunities to reform drug policy: a case study into the development of the Australian "Tough on Drugs-Illicit Drug Diversion Initiative".
    Hughes CE
    Int J Drug Policy; 2009 Sep; 20(5):431-7. PubMed ID: 19162458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intergovernmental health policy decisions in Brazil: cooperation strategies for political mediation.
    Miranda AS
    Health Policy Plan; 2007 May; 22(3):186-92. PubMed ID: 17485420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences of breast cancer survivor-advocates and advocates in countries with limited resources: a shared journey in breast cancer advocacy.
    Errico KM; Rowden D
    Breast J; 2006; 12 Suppl 1():S111-6. PubMed ID: 16430394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advocacy groups for breast cancer patients.
    Waller M; Batt S
    CMAJ; 1995 Mar; 152(6):829-33. PubMed ID: 7697576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug Reimbursement System--cost containment and patient advocacy].
    van der Kuy A
    TVZ; 1992 Apr; (7):249-51. PubMed ID: 1575931
    [No Abstract]   [Full Text] [Related]  

  • 12. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):81-9. PubMed ID: 15607936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of budget impact in drug reimbursement decisions.
    Cohen JP; Stolk E; Niezen M
    J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public health policy decisions on medical innovations: what role can early economic evaluation play?
    Hartz S; John J
    Health Policy; 2009 Feb; 89(2):184-92. PubMed ID: 18619704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
    Pikó B;
    Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
    [No Abstract]   [Full Text] [Related]  

  • 17. What influences the transfer of research into health policy and practice? Observations from England and Australia.
    Nutbeam D; Boxall AM
    Public Health; 2008 Aug; 122(8):747-53. PubMed ID: 18561966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic decision making in Europe--a new priority for breast cancer advocacy.
    Knox S
    Breast; 2009 Apr; 18(2):71-2. PubMed ID: 19380086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.